{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T07:49:25Z","timestamp":1776930565953,"version":"3.51.2"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.yebeh.2019.106832","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T09:13:31Z","timestamp":1576142011000},"page":"106832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"PB","title":["Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment"],"prefix":"10.1016","volume":"121","author":[{"given":"Laila","family":"Asth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lia P.","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio C.","family":"De Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcio F.D.","family":"Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabr\u00edcio A.","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.yebeh.2019.106832_bb0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S1516-44462006000200015","article-title":"History of cannabis as a medicine: a review","volume":"28","author":"Zuardi","year":"2006","journal-title":"Rev Bras Psiquiatr"},{"issue":"11","key":"10.1016\/j.yebeh.2019.106832_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/nrn3811","article-title":"Early phytocannabinoid chemistry to endocannabinoids and beyond","volume":"15","author":"Mechoulam","year":"2014","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.1016\/j.yebeh.2019.106832_bb0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol Pharmacol"},{"issue":"6284","key":"10.1016\/j.yebeh.2019.106832_bb0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"issue":"6441","key":"10.1016\/j.yebeh.2019.106832_bb0025","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"issue":"5090","key":"10.1016\/j.yebeh.2019.106832_bb0030","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"issue":"6604","key":"10.1016\/j.yebeh.2019.106832_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/384083a0","article-title":"Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides","volume":"384","author":"Cravatt","year":"1996","journal-title":"Nature"},{"issue":"6507","key":"10.1016\/j.yebeh.2019.106832_bb0040","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/372686a0","article-title":"Formation and inactivation of endogenous cannabinoid anandamide in central neurons","volume":"372","author":"Di Marzo","year":"1994","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.yebeh.2019.106832_bb0045","doi-asserted-by":"crossref","first-page":"10819","DOI":"10.1073\/pnas.152334899","article-title":"Brain monoglyceride lipase participating in endocannabinoid inactivation","volume":"99","author":"Dinh","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1410","key":"10.1016\/j.yebeh.2019.106832_bb0050","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1098\/rspb.1998.0543","article-title":"A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain","volume":"265","author":"Egertova","year":"1998","journal-title":"Proc Biol Sci"},{"issue":"6828","key":"10.1016\/j.yebeh.2019.106832_bb0055","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/35069076","article-title":"Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses","volume":"410","author":"Wilson","year":"2001","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.yebeh.2019.106832_bb0060","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrd.2018.115","article-title":"New approaches and challenges to targeting the endocannabinoid system","volume":"17","author":"Di Marzo","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0065","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB\u2081 and CB\u2082","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol Rev"},{"issue":"11","key":"10.1016\/j.yebeh.2019.106832_bb0070","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"10.1016\/j.yebeh.2019.106832_bb0075","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/sj.bjp.0705467","article-title":"Anandamide and vanilloid TRPV1 receptors","volume":"140","author":"Ross","year":"2003","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0080","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/sj.bjp.0703850","article-title":"Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens","volume":"132","author":"Ross","year":"2001","journal-title":"Br J Pharmacol"},{"issue":"6743","key":"10.1016\/j.yebeh.2019.106832_bb0085","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/22761","article-title":"Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide","volume":"400","author":"Zygmunt","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.yebeh.2019.106832_bb0090","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuroscience.2011.08.046","article-title":"Cannabinoid type 1 receptors and transient receptor potential vanilloid type 1 channels in fear and anxiety-two sides of one coin?","volume":"204","author":"Moreira","year":"2012","journal-title":"Neuroscience"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0095","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2019.106832_bb0100","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMcp0801738","article-title":"Clinical practice. Initial management of epilepsy","volume":"359","author":"French","year":"2008","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0105","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1528-1167.2011.03391.x","article-title":"Identification of new epilepsy treatments: issues in preclinical methodology","volume":"53","author":"Galanopoulou","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106832_bb0110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/NDT.S50371","article-title":"Animal models of epilepsy: use and limitations","volume":"10","author":"Kandratavicius","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.yebeh.2019.106832_bb0115","article-title":"The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments","volume":"107605","author":"Loscher","year":"2019","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0120","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1528-1167.2011.03024.x","article-title":"Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma","volume":"52","author":"Loscher","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106832_bb0125","doi-asserted-by":"crossref","first-page":"573","DOI":"10.3389\/fphar.2018.00573","article-title":"Preclinical animal models for Dravet syndrome: seizure phenotypes, comorbidities and drug screening","volume":"9","author":"Griffin","year":"2018","journal-title":"Front Pharmacol"},{"issue":"8","key":"10.1016\/j.yebeh.2019.106832_bb0130","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.2042-7158.1973.tb10660.x","article-title":"Letter: cannabidiol and Cannabis sativa extract protect mice and rats against convulsive agents","volume":"25","author":"Carlini","year":"1973","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.yebeh.2019.106832_bb0135","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.neuro.2015.08.007","article-title":"Cannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: possible role of the mTOR pathway and reduction in glutamate release","volume":"50","author":"Gobira","year":"2015","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.yebeh.2019.106832_bb0140","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/523418","article-title":"Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine","author":"Vilela","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0145","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s12031-015-0703-6","article-title":"Cannabidiol post-treatment alleviates rat epileptic-related behaviors and activates hippocampal cell autophagy pathway along with antioxidant defense in chronic phase of pilocarpine-induced seizure","volume":"58","author":"Hosseinzadeh","year":"2016","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.yebeh.2019.106832_bb0150","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.yebeh.2017.04.045","article-title":"Assessing the role of serotonergic receptors in cannabidiol's anticonvulsant efficacy","volume":"73","author":"Pelz","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106832_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","article-title":"Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels","volume":"75","author":"Vilela","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2019.106832_bb0160","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of Cannabidiol in animal seizure models by the epilepsy therapy screening program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem Res"},{"issue":"42","key":"10.1016\/j.yebeh.2019.106832_bb0165","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.yebeh.2019.106832_bb0170","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1590\/S1516-44462008000300015","article-title":"Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action","volume":"30","author":"Zuardi","year":"2008","journal-title":"Braz J Psychiatry"},{"issue":"1","key":"10.1016\/j.yebeh.2019.106832_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(01)01243-2","article-title":"Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects","volume":"428","author":"Wallace","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"Pt 8","key":"10.1016\/j.yebeh.2019.106832_bb0185","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/brain\/aww129","article-title":"Aberrant epilepsy-associated mutant Nav1.6 sodium channel activity can be targeted with cannabidiol","volume":"139","author":"Patel","year":"2016","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.yebeh.2019.106832_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nurt.2006.11.005","article-title":"Currently available antiepileptic drugs","volume":"4","author":"Schachter","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.yebeh.2019.106832_bb0195","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1111\/j.1528-1167.2010.02523.x","article-title":"\u03949-Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats","volume":"51","author":"Hill","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0200","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","article-title":"Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism","volume":"170","author":"Hill","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.yebeh.2019.106832_bb0205","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.yebeh.2015.12.040","article-title":"Anticonvulsant activity of \u03b2-caryophyllene against pentylenetetrazol-induced seizures","volume":"56","author":"de Oliveira","year":"2016","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106832_bb0210","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.seizure.2018.03.009","article-title":"Pharmacological characterization of the cannabinoid receptor 2 agonist, \u03b2-caryophyllene on seizure models in mice","volume":"57","author":"Tchekalarova","year":"2018","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0215","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.neuropharm.2009.06.007","article-title":"Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy","volume":"57","author":"Blair","year":"2009","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0220","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/jpet.105.100354","article-title":"Activation of the cannabinoid type-1 receptor mediates the anticonvulsant properties of cannabinoids in the hippocampal neuronal culture models of acquired epilepsy and status epilepticus","volume":"317","author":"Blair","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.yebeh.2019.106832_bb0225","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010683","article-title":"Cannabinoid-mediated inhibition of recurrent excitatory circuitry in the dentate gyrus in a mouse model of temporal lobe epilepsy","volume":"5","author":"Bhaskaran","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.yebeh.2019.106832_bb0230","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1111\/j.1528-1167.2011.03079.x","article-title":"Targeting the endocannabinoid system in the amygdala kindling model of temporal lobe epilepsy in mice","volume":"52","author":"Wendt","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.106832_bb0235","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2016.08.004","article-title":"The cannabinoid receptor agonist WIN55.212 reduces consequences of status epilepticus in rats","volume":"334","author":"Suleymanova","year":"2016","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.yebeh.2019.106832_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pnpbp.2009.09.005","article-title":"Effect of arachidonyl-2\u2032-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock-induced seizure model","volume":"34","author":"Luszczki","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"9","key":"10.1016\/j.yebeh.2019.106832_bb0245","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1111\/epi.13842","article-title":"Anticonvulsant effect of cannabinoid receptor agonists in models of seizures in developing rats","volume":"58","author":"Huizenga","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0250","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.neuropharm.2004.04.011","article-title":"The interaction of cannabinoids and opioids on pentylenetetrazole-induced seizure threshold in mice","volume":"47","author":"Shafaroodi","year":"2004","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.eplepsyres.2012.11.006","article-title":"Effects of cannabinoids and endocannabinoid hydrolysis inhibition on pentylenetetrazole-induced seizure and electroencephalographic activity in rats","volume":"104","author":"Vilela","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.106832_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2017.10.007","article-title":"Synthetic cannabinoid AM2201 induces seizures: involvement of cannabinoid CB","volume":"338","author":"Funada","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"issue":"11","key":"10.1016\/j.yebeh.2019.106832_bb0265","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1523\/JNEUROSCI.19-11-04544.1999","article-title":"Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons","volume":"19","author":"Katona","year":"1999","journal-title":"J Neurosci"},{"issue":"5642","key":"10.1016\/j.yebeh.2019.106832_bb0270","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.1088208","article-title":"CB1 cannabinoid receptors and on-demand defense against excitotoxicity","volume":"302","author":"Marsicano","year":"2003","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0275","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.neuron.2006.07.006","article-title":"The endocannabinoid system controls key epileptogenic circuits in the hippocampus","volume":"51","author":"Monory","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.yebeh.2019.106832_bb0280","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.nbd.2014.08.001","article-title":"Analysis in conditional cannabinoid 1 receptor-knockout mice reveals neuronal subpopulation-specific effects on epileptogenesis in the kindling paradigm","volume":"73","author":"von R\u00fcden","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.yebeh.2019.106832_bb0285","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0290","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0014-2999(02)02331-2","article-title":"Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity","volume":"452","author":"Wallace","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.yebeh.2019.106832_bb0295","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1528-1167.2009.02334.x","article-title":"Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy","volume":"51","author":"Romigi","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0300","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s12031-010-9472-4","article-title":"A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity","volume":"43","author":"Naidoo","year":"2011","journal-title":"J Mol Neurosci"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0305","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s13311-011-0100-y","article-title":"Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology","volume":"9","author":"Naidoo","year":"2012","journal-title":"Neurotherapeutics"},{"issue":"1","key":"10.1016\/j.yebeh.2019.106832_bb0310","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11606-1","article-title":"The FAAH inhibitor URB597 suppresses hippocampal maximal dentate afterdischarges and restores seizure-induced impairment of short and long-term synaptic plasticity","volume":"7","author":"Colangeli","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.yebeh.2019.106832_bb0315","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.nbd.2015.03.016","article-title":"Inhibition of monoacylglycerol lipase mediates a cannabinoid 1-receptor dependent delay of kindling progression in mice","volume":"77","author":"von R\u00fcden","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"9","key":"10.1016\/j.yebeh.2019.106832_bb0320","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1523\/JNEUROSCI.23-09-03916.2003","article-title":"Increased seizure susceptibility and proconvulsant activity of anandamide in mice lacking fatty acid amide hydrolase","volume":"23","author":"Clement","year":"2003","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.yebeh.2019.106832_bb0325","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.expneurol.2010.01.021","article-title":"Effects of TRPV1 activation on synaptic excitation in the dentate gyrus of a mouse model of temporal lobe epilepsy","volume":"223","author":"Bhaskaran","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.yebeh.2019.106832_bb0330","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.yebeh.2013.10.022","article-title":"Role of TRPV1 in susceptibility to PTZ-induced seizure following repeated hyperthermia challenges in neonatal mice","volume":"31","author":"Kong","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.106832_bb0335","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.neuroscience.2015.11.045","article-title":"TRPV1 receptors augment basal synaptic transmission in CA1 and CA3 pyramidal neurons in epilepsy","volume":"314","author":"Saffarzadeh","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.yebeh.2019.106832_bb0340","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.expneurol.2013.10.010","article-title":"TRPV1 antagonist capsazepine suppresses 4-AP-induced epileptiform activity in vitro and electrographic seizures in vivo","volume":"250","author":"Gonzalez-Reyes","year":"2013","journal-title":"Exp Neurol"},{"issue":"1\u20133","key":"10.1016\/j.yebeh.2019.106832_bb0345","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ejphar.2013.07.041","article-title":"Piperine exerts anti-seizure effects via the TRPV1 receptor in mice","volume":"714","author":"Chen","year":"2013","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"10.1016\/j.yebeh.2019.106832_bb0350","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00702-015-1391-7","article-title":"\u03b1-Spinasterol, a TRPV1 receptor antagonist, elevates the seizure threshold in three acute seizure tests in mice","volume":"122","author":"Soca\u0142a","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"issue":"8","key":"10.1016\/j.yebeh.2019.106832_bb0355","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s10072-014-1689-5","article-title":"Involvement of central TRPV1 receptors in pentylenetetrazole and amygdala-induced kindling in male rats","volume":"35","author":"Shirazi","year":"2014","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.yebeh.2019.106832_bb0360","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/cns.12770","article-title":"Inhibition of transient potential receptor vanilloid type 1 suppresses seizure susceptibility in the genetically epilepsy-prone rat","volume":"24","author":"Cho","year":"2018","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.yebeh.2019.106832_bb0365","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.neuroscience.2015.02.041","article-title":"Involvement of apoptosis and calcium accumulation through TRPV1 channels in neurobiology of epilepsy","volume":"293","author":"Naz\u0131ro\u011flu","year":"2015","journal-title":"Neuroscience"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2019.106832_bb0370","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11010-018-3439-0","article-title":"Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model","volume":"453","author":"Naz\u0131ro\u011flu","year":"2019","journal-title":"Mol Cell Biochem"},{"issue":"1\u20132","key":"10.1016\/j.yebeh.2019.106832_bb0375","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.eplepsyres.2012.02.003","article-title":"Involvement of transient receptor potential vanilloid type 1 channels in the pro-convulsant effect of anandamide in pentylenetetrazole-induced seizures","volume":"100","author":"Manna","year":"2012","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.yebeh.2019.106832_bb0380","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/bcpt.12232","article-title":"Anticonvulsant effects of N-arachidonoyl-serotonin, a dual fatty acid amide hydrolase enzyme and transient receptor potential vanilloid type-1 (TRPV1) channel blocker, on experimental seizures: the roles of cannabinoid CB1 receptors and TRPV1 channels","volume":"115","author":"Vilela","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.yebeh.2019.106832_bb0385","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.eplepsyres.2016.02.005","article-title":"Involvement of TRPV1 channels in the activity of the cannabinoid WIN 55,212-2 in an acute rat model of temporal lobe epilepsy","volume":"122","author":"Carletti","year":"2016","journal-title":"Epilepsy Res"},{"issue":"S1","key":"10.1016\/j.yebeh.2019.106832_bb0390","doi-asserted-by":"crossref","first-page":"417S","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","article-title":"Hypnotic and antiepileptic effects of cannabidiol","volume":"21","author":"Carlini","year":"1981","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0395","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000137430","article-title":"Chronic administration of cannabidiol to healthy volunteers and epileptic patients","volume":"21","author":"Cunha","year":"1980","journal-title":"Pharmacology"},{"issue":"20","key":"10.1016\/j.yebeh.2019.106832_bb0400","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of Cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"10125","key":"10.1016\/j.yebeh.2019.106832_bb0405","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.yebeh.2019.106832_bb0410","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0415","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.yebeh.2013.08.037","article-title":"Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy","volume":"29","author":"Porter","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.yebeh.2019.106832_bb0420","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019303737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:46:13Z","timestamp":1761504373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019303737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":84,"alternative-id":["S1525505019303737"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106832","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploiting cannabinoid and vanilloid mechanisms for epilepsy treatment","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.106832","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106832"}}